1032

ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND SUBSTUDY

Date
May 9, 2023
Explore related products in the following collection:

Loading...

Tracks

Related Products

Thumbnail for SUBCUTANEOUS INFLIXIMAB (CT-P13) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (LIBERTY-CD).
SUBCUTANEOUS INFLIXIMAB (CT-P13) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (LIBERTY-CD).
BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Thumbnail for DEVELOPMENT AND VALIDATION OF A NOVEL COMPOSITE INDEX FOR THE ASSESSMENT OF ENDOSCOPIC AND HISTOLOGIC DISEASE ACTIVITY IN POUCHITIS: THE ATLANTIC POUCHITIS INDEX
DEVELOPMENT AND VALIDATION OF A NOVEL COMPOSITE INDEX FOR THE ASSESSMENT OF ENDOSCOPIC AND HISTOLOGIC DISEASE ACTIVITY IN POUCHITIS: THE ATLANTIC POUCHITIS INDEX
BACKGROUND: Anti-granulocyte macrophage-colony stimulating factor autoantibodies (anti-GM-CSF) have been associated with development of Crohn’s disease (CD) and complications at time of diagnosis. There are limited data on anti-GM-CSF as a prognostic biomarker in CD…
Thumbnail for UNITED STATES AND EUROPEAN PATIENT PERSPECTIVES ON THE IMPACT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS ON SEXUAL ACTIVITY: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
UNITED STATES AND EUROPEAN PATIENT PERSPECTIVES ON THE IMPACT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS ON SEXUAL ACTIVITY: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
Background: Patients with inflammatory bowel disease (IBD) often modify their diet in attempt to manage their disease and symptoms. In some cases, dietary changes involve excessive restriction, which may place patients at risk for adverse consequences…
Thumbnail for VEDOLIZUMAB PREVENTS POSTOPERATIVE REUCURRENCE IN CROHN’S DISEASE: RESULTS OF THE REPREVIO TRIAL
VEDOLIZUMAB PREVENTS POSTOPERATIVE REUCURRENCE IN CROHN’S DISEASE: RESULTS OF THE REPREVIO TRIAL
This session presents the best submitted clinical abstracts as determined by their specific council sections…